Xilio Therapeutics Advances Pipeline with IND Plans for XTX501 and Strong Cash Runway
Event summary
- XTX501, a bispecific PD-1/masked IL-2, is on track for IND submission in mid-2026 and Phase 1 initiation in the second half of 2026.
- XTX601, a masked T cell engager targeting CLDN18.2, presented promising preclinical data at AACR, demonstrating tumor-selective activation and potent anti-tumor activity.
- Xilio achieved a $6.0 million development milestone under its AbbVie collaboration, extending its cash runway into early 2028.
- Cash and cash equivalents increased to $150.3 million as of March 31, 2026, driven by a $37.3 million follow-on offering in February 2026.
The big picture
Xilio Therapeutics is advancing its pipeline of masked immuno-oncology therapies, with XTX501 poised to become a foundational therapy for combination treatments in solid tumors. The company's strong cash position and strategic collaborations with AbbVie and Gilead underscore its ability to maximize the value of its clinically-validated masking technology. The progress in its masked T cell engager programs highlights the potential to address tumor heterogeneity and minimize resistance, positioning Xilio as a key player in the immuno-oncology space.
What we're watching
- Regulatory Timelines
- Whether XTX501's IND submission will be cleared by the FDA as planned, enabling Phase 1 initiation in the second half of 2026.
- Clinical Data
- The pace at which XTX601 and the PSMA+STEAP1 program advance through IND-enabling activities and potential IND submissions in 2027.
- Financial Strategy
- How Xilio will leverage its extended cash runway and potential additional milestone payments from AbbVie and Gilead to fund its operating expenses into early 2028.
Related topics